NEW: No-Cost Streetwise Live! Events. This type of intellectual capital is usually not made available to the general public. Learn More

Get the Latest Investment Ideas Delivered Straight to Your Inbox.

News Update

TICKERS: RVV; RVVTF

Biotech Partners with University to Evaluate Psilocybin for Treating Methamphetamine Use Disorder
News Update

Share on Stocktwits

Source:

Revive Therapeutics reported it has entered into clinical trial agreement with the University of Wisconsin-Madison to evaluate the use of psilocybin for the treatment of methamphetamine use disorder.

In a news release, Revive Therapeutics Ltd. (RVV:TSX.V; RVVTF:OTCMKTS) announced that it has entered into a Clinical Trial Agreement (CTA) with the University of Wisconsin System's (UWS) Board of Regents. The CTA was signed on August 28, 2020, and was established in order to initiate a clinical study entitled, "Phase I Study of the Safety and Feasibility of Psilocybin in Adults with Methamphetamine Use Disorder."

The company stated that CTA terms provide Revive Therapeutics with "an exclusive option to obtain an exclusive, worldwide, royalty-bearing commercialization license to all rights, title and interest that UWS may have or obtain in any invention that results from the clinical study."

Revive Therapeutics CEO Michael Frank remarked, "We are delighted to be collaborating with clinical researchers at the University of Wisconsin‒Madison to advance development of psilocybin for the potential treatment of methamphetamine use disorder...We are building a pipeline of clinical-stage psychedelic-derived therapies for addiction disorders with a focus on psilocybin with unique dosage forms."

The firm stated that the clinical study will take place at the University of Wisconsin Schools of Medicine and Public Health and Pharmacy which has been granted a Wisconsin special authorization and Drug Enforcement Administration license to carryout psilocybin clinical research.

The company stated that Assistant Professor and clinical psychologist Christopher R. Nicholas, Ph.D., at the University of Wisconsin School of Medicine and Public Health's Program for Research Outreach Therapeutics and Education in the Addictions (PROTEA) in the Department of Family Medicine and Community Health, will serve as principal investigator for the initial safety study. The PROTEA team has already completed significant amounts of research involving the pharmacokinetics of high-dose psilocybin and is now additionally investigating the potential for psilocybin as an opioid use disorder treatment.

The company indicated that methamphetamine use disorder is caused by frequent and recurrent use of methamphetamine and that according to a 2018 National Survey on Drug Use and Health conducted by the Substance Abuse and Mental Health Services Administration, there are around 1.1 million people in the U.S aged 12 or older who have a methamphetamine use disorder. The firm noted that currently there are no approved pharmaceutical treatments approved for methamphetamine dependence. At present, treatment approaches are limited to using behavioral modification therapies, such as cognitive-behavioral therapy to change thinking patterns based upon what a patient is feeling and contingency management interventions employing behavior analysis assessments and techniques.

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Revive Therapeutics. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Revive Therapeutics, a company mentioned in this article.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.




Learn More about Streetwise Reports Live

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe